MRI T2 Hypointensities in basal ganglia of premanifest Huntington's disease - PubMed (original) (raw)

MRI T2 Hypointensities in basal ganglia of premanifest Huntington's disease

Caroline K Jurgens et al. PLoS Curr. 2010.

Abstract

Increased iron levels have been demonstrated in the basal ganglia of manifest Huntington's disease (HD). An excess in iron accumulation correlates with MRI T2-weighted hypointensity. Determination of the amount of hypointensities in the basal ganglia in the premanifest phase of HD may give more insight in the role of iron in the pathogenesis of HD. Therefore, the present study assessed whether the degree of hypointensities on T2-w MRI in the basal ganglia of premanifest gene carriers differs from non-carriers. Seventeen HD gene carriers without clinical motor signs and 15 non-carriers underwent clinical evaluation and MRI scanning. The amount of T2-w hypointensities was determined using a computer-assisted quantitative method that classified each pixel in the basal ganglia as hypointense or not, resulting in a total of hypointense pixels for each individual. Carriers showed an increased amount of hypointensities in the basal ganglia compared to non-carriers. More hypointensities were furthermore associated with a higher UHDRS total motor score, a longer CAG repeat length and a greater probability of developing symptoms within 5 years. We concluded that the increased amount of hypointensities in the basal ganglia of premanifest carriers of the HD gene may reflect excessive iron deposition and a role for iron in the neuropathology of HD. Furthermore, this phenomenon is associated with clinical and biological disease characteristics. An increased amount of hypointensities on T2-w MRI in the basal ganglia may be considered a biomarker for HD.

PubMed Disclaimer

Figures

Similar articles

Cited by

References

    1. Bates G, Harper PS, Jones L. Huntington's disease, Third ed. Oxford University Press, 2002.
    1. Berg D, Gerlach M, Youdim MB, et al. Brain iron pathways and their relevance to Parkinson's disease. J Neurochem 2001; 79:225-236. - PubMed
    1. Zecca L, Youdim MB, Riederer P, et al. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004; 5:863-873. - PubMed
    1. Gotz ME, Double K, Gerlach M, et al. The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 2004; 1012:193-208. - PubMed
    1. Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991; 114:1953-1975. - PubMed

LinkOut - more resources